Is Adagraxibu available for sale in Hong Kong?

Adagrasib (Adagrasib, branded as Krazati, is an anti-cancer drug used to treat non-small cell lung cancer. Adagrasiib is an inhibitor of the RAS GTPase family , it is an oral drug. Since adagrasibthe original drug has not yet been launched in China, pharmacies such as Hong Kong may not have the drug for sale. Patients can currently only purchase the original drug of adagrasibu through relevant overseas channels.

Adagrasibis mainlyindicated for the treatment of solid tumors containing KRAS G12C oncogenic driver mutations, including non-small cell lung cancer (NSCLC). KRAS mutations are very common in cancer, accounting for approximately 85% of all RAS family mutations. Adagrasib covalently binds to the mutant cysteine u200bu200bin KRAS G12C and locks the mutant KRAS protein in an inactive state, thereby preventing downstream signaling without affecting the wild-type KRAS protein. The most common adverse reactions include diarrhea, nausea, fatigue, vomiting, musculoskeletal pain, hepatotoxicity, renal impairment, dyspnea, edema, decreased appetite, cough, pneumonia, dizziness, constipation, abdominal pain and QTc interval prolongation. The most common laboratory abnormalities include lymphopenia, increased aspartate aminotransferase, decreased sodium, decreased hemoglobin, increased creatinine, decreased albumin, increased alanine aminotransferase, increased lipase, decreased platelets, decreased magnesium, and decreased potassium.

AdagrasibOnly the American original research version is sold overseas, with common specificationsThe price of each box of 200mg*180 tablets is more than 100,000 yuan (the price may fluctuate due to the exchange rate), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. For more drug information and specific prices, please consult Yaode’s medical consultant.